- Home
- ROIV vs CRDO Comparison
ROIV vs CRDO Comparison
Compare ROIV & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CRDO
- Stock Information
- Founded
- ROIV 2014
- CRDO 2008
- Country
- ROIV United Kingdom
- CRDO Cayman Islands
- Employees
- ROIV N/A
- CRDO N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CRDO Semiconductors
- Sector
- ROIV Health Care
- CRDO Technology
- Exchange
- ROIV Nasdaq
- CRDO Nasdaq
- Market Cap
- ROIV 8.6B
- CRDO 18.9B
- IPO Year
- ROIV N/A
- CRDO 2022
- Fundamental
- Price
- ROIV $15.28
- CRDO $164.44
- Analyst Decision
- ROIV Strong Buy
- CRDO Strong Buy
- Analyst Count
- ROIV 4
- CRDO 11
- Target Price
- ROIV $15.50
- CRDO $129.91
- AVG Volume (30 Days)
- ROIV 7.8M
- CRDO 5.4M
- Earning Date
- ROIV 11-11-2025
- CRDO 09-03-2025
- Dividend Yield
- ROIV N/A
- CRDO N/A
- EPS Growth
- ROIV N/A
- CRDO N/A
- EPS
- ROIV N/A
- CRDO 0.67
- Revenue
- ROIV $23,233,000.00
- CRDO $600,135,000.00
- Revenue This Year
- ROIV N/A
- CRDO $94.77
- Revenue Next Year
- ROIV $281.14
- CRDO $27.66
- P/E Ratio
- ROIV N/A
- CRDO $244.33
- Revenue Growth
- ROIV N/A
- CRDO 175.81
- 52 Week Low
- ROIV $8.73
- CRDO $26.96
- 52 Week High
- ROIV $16.05
- CRDO $168.42
- Technical
- Relative Strength Index (RSI)
- ROIV 82.00
- CRDO 75.89
- Support Level
- ROIV $13.81
- CRDO $116.16
- Resistance Level
- ROIV $14.48
- CRDO $168.14
- Average True Range (ATR)
- ROIV 0.47
- CRDO 8.03
- MACD
- ROIV 0.22
- CRDO 2.55
- Stochastic Oscillator
- ROIV 81.67
- CRDO 92.38
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.